Ulcerative colitis
Conditions
Interventions
experimental group 1:Lactobacillus plantarum CCFM8610
experimental group 2:Lactobacillus plantarum N13
experimental group 3:Lactobacillus casei CCFM1059
Sponsors
Jiangnan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. UC patients aged 18-65 years, both male and female; 2. Patients who have good compliance and are able to comply with the requirements of the clinical trial, and promise to cooperate with the study during the whole experimental period; 3. Patients who meet UC diagnostic criteria and are diagnosed with UC. UC is in the active stage, the degree is light or moderate, the ucdai score is between 3-9; 4. Patients who fill in the written informed consent and the quality of life certificate of inflammatory bowel disease.
Exclusion criteria
Exclusion criteria: 1. Patients with serious liver, kidney, heart, respiratory system diseases, endocrine diseases, inflammatory diseases and mental diseases diagnosed by the hospital; 2. Patients with gastrointestinal infection and other gastrointestinal diseases diagnosed by the hospital; 3. Patients who have had major abdominal surgery, especially gastrointestinal surgery; 4. Patients with gastrointestinal cancer or IBS; 5. Patients with severe UC symptoms who need operation urgently; 6. Patients who are allergic to mesalazine and whose dosage has changed in the past month (mesalazine is allowed); 7. Patients with other types of immune system diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Graves disease, psoriasis, etc; 8. The current or recent (1 month) or long-term use of antibiotics, the current or recent (3 months) or long-term use of glucocorticoids (such as cortisol), steroids, immunosuppressive drugs or biological targeted drugs; 9. Patients who take probiotics, microecological preparations and dietary supplements in the near future (within one month) or for a long time; 10. Patients with significant changes in their eating habits in the near future (within one month), such as starting to eat a fiber rich diet; 11. Patients who are allergic to the ingredients of experimental probiotic products or lactose intolerant; 12. For women, patients who are pregnant, breastfeeding or wish to be pregnant; 13. Patients who are currently or in the near future (within 3 months) in other clinical studies; 14. Patients who cannot tolerate or accept colonoscopy; 15. Patients who are unwilling or unable to provide written informed consent to participate in the study after the researcher informs the researcher of the purpose, process and possible risks; 16. Patients who do not meet the requirements of the study or who the researchers believe should not participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C-Reactive Protein;Fecal occult blood;Ulcerative colitis disease activity index;Ulcerative colitis endoscopic index of severity;Inflammatory bowel disease quality of life scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum IL-1ß;Serum IL-6;Serum TNF-a;Serum IFN-?;Serum myeloperoxidase;Serum IL-10;Fecal calprotectin;Fecal microbiota;Fecal short-chain fatty acid; | — |
Countries
China
Contacts
Public ContactQixiao Zhai
Jiangnan University
Outcome results
None listed